CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-2.45%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.72B
AUM Growth
+$1.72B
(-24%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-13.93%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
67
New
8
Increased
11
Reduced
11
Closed
17
Top Buys
| 1 |
RAPP
Rapport Therapeutics
RAPP
|
$68.4M |
| 2 |
Axsome Therapeutics
AXSM
|
$32.2M |
| 3 |
Vaxcyte
PCVX
|
$31.3M |
| 4 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$28.6M |
| 5 |
UroGen Pharma
URGN
|
$27.7M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$107M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$44.6M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
$42.2M |
| 4 |
ALX Oncology
ALXO
|
$35M |
| 5 |
BridgeBio Pharma
BBIO
|
$34.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $373M | 21.58% | 8,494,151 | – | – |
|
2
Corbus Pharmaceuticals
CRBP
$115M
| $91.6M | 5.29% | 2,025,000 | – | – |
|
3
Arcellx
ACLX
$3.85B
| $84.2M | 4.86% | 1,525,000 -255,000 | -14% | -$14.1M |
|
|
4
Vaxcyte
PCVX
$4B
| $83.1M | 4.8% | 1,100,000 +415,000 | +61% | +$31.3M |
|
|
LBPH
5
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $75.4M | 4.36% | 2,790,462 -562,679 | -17% | -$15.2M |
|
6
EyePoint Pharmaceuticals
EYPT
$797M
| $72.4M | 4.18% | 8,325,000 +1,431,765 | +21% | +$12.5M |
|
|
RAPP
7
Rapport Therapeutics
RAPP
$643M
| $68.4M | 3.95% | +2,940,283 | New | +$68.4M |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $60.5M | 3.49% | 1,350,000 +200,000 | +17% | +$8.96M |
|
9
Edgewise Therapeutics
EWTX
$1.51B
| $54.1M | 3.13% | 3,006,534 | – | – |
|
10
Merus
MRUS
$4.98B
| $49.7M | 2.87% | 840,000 +125,000 | +17% | +$7.4M |
|
|
11
BridgeBio Pharma
BBIO
$9.89B
| $47.1M | 2.72% | 1,858,351 -1,344,678 | -42% | -$34.1M |
|
12
Insmed
INSM
$28.8B
| $45.2M | 2.61% | 675,000 +100,000 | +17% | +$6.7M |
|
13
NewAmsterdam Pharma
NAMS
$2.71B
| $44.2M | 2.55% | 2,300,000 +800,000 | +53% | +$15.4M |
|
14
Janux Therapeutics
JANX
$1.37B
| $44M | 2.54% | 1,050,000 +300,000 | +40% | +$12.6M |
|
|
15
Axsome Therapeutics
AXSM
$6.05B
| $32.2M | 1.86% | +400,000 | New | +$32.2M |
|
16
CG Oncology
CGON
$2.04B
| $30.8M | 1.78% | 975,000 +175,000 | +22% | +$5.52M |
|
|
BBOT
17
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $29.7M | 1.72% | 2,909,000 | – | – |
|
|
ALMS
18
Alumis Inc. Common Stock
ALMS
$479M
| $28.6M | 1.65% | +2,147,400 | New | +$28.6M |
|
19
Praxis Precision Medicines
PRAX
$958M
| $28.3M | 1.64% | 685,000 -625,000 | -48% | -$25.9M |
|
|
ABVX
20
Abivax
ABVX
$6.12B
| $28.2M | 1.63% | 2,130,000 | – | – |
|
21
Biohaven
BHVN
$1.63B
| $27.8M | 1.61% | 801,963 +185,000 | +30% | +$6.42M |
|
|
22
UroGen Pharma
URGN
$900M
| $27.7M | 1.6% | +1,650,000 | New | +$27.7M |
|
23
Pharvaris
PHVS
$1.39B
| $27.6M | 1.59% | 1,466,460 -245,000 | -14% | -$4.61M |
|
24
Arcutis Biotherapeutics
ARQT
$1.86B
| $23.5M | 1.36% | 2,525,000 +400,000 | +19% | +$3.72M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $19.8M | 1.14% | +125,000 | New | +$19.8M |
|